DNA damage response and its clinical implications in pediatric cancers

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The DNA damage response (DDR) network maintains genetic stability in eukaryotes.
• Altered DDR pathways are common in cancer, presenting both vulnerabilities and survival advantages.
• Targeting DDR, notably with PARP inhibitors, has shown clinical success in various cancers.

Purpose of the Study:

• To review recent advancements in DNA damage response (DDR) and its inhibitors.
• Focus on the application of DDR inhibitors in pediatric cancers.
• Discuss the molecular mechanisms and clinical implications.

Main Methods:

• Literature review of recent studies on DDR and cancer.
• Analysis of molecular mechanisms underlying DDR alterations in cancer.
• Examination of clinical trial data for DDR inhibitors in pediatric oncology.

Main Results:

• DDR defects can drive cancer mutations or confer survival benefits.
• PARP inhibitors are a key therapeutic strategy targeting DDR defects.
• Emerging data highlights the potential of DDR inhibitors in pediatric cancers.

Conclusions:

• DDR plays a complex role in cancer, offering therapeutic targets.
• Targeting DDR with inhibitors like PARP inhibitors is a promising strategy for pediatric cancers.
• Further research is needed to optimize DDR-targeted therapies in pediatric oncology.